曲妥珠单抗联合吉西他滨治疗ＨＥＲ２阳性的转移性乳腺癌

目的：探讨曲妥珠单抗（赫赛汀）联合吉西他滨（ＧＥＭ）治疗表皮生长因子受体２（ＨＥＲ２）阳性的转移性乳腺癌（ＭＢＣ）的疗效和不良反应。方法：ＨＥＲ２阳性的ＭＢＣ女性患者９例，给予ＧＥＭ１０００ｍｇ／ｍ^２，静脉滴注，ｄ１、ｄ８、ｄ１５，４周重复；赫赛汀静脉滴注，首次４ｍｇ／ｋｇ，其后每周１次，２ｍｇ／ｋｇ，连续使用。结果：９例患者中，ＣＲ１例（１１.１％），ＰＲ６例（６６.７％），ＳＤ和ＰＤ各１例（１１.１％），有效率（ＲＲ）为７７.８％，疾病控制率（ＤＣＲ）为８８.９％；中位肿瘤进展时间（ＴＴＰ）为１８个月，中位总生存时间（ＯＳ）为２３个月。主要毒性反应是骨髓抑制和消化道反应，且均为Ⅰ ～Ⅱ度。结论：赫赛汀联合吉西他滨对于难治性转移性乳腺癌是有效且安全的治疗方案。

Trastuzumab in combination with gemcitabine as salvage therapy in metastatic breast cancer with Her2-positive

Objective：To evaluate the efficacy and safety of trastuzumab in combination with gemcitabine as salvage therapy in metastatic breast cancer with Her2-positive.Methods：Nine consecutive patients were included as eligible.Patients received gemcitabine at a dose of 1 000mg/m2 on day 1,8,15,every 28 days.Trastuzumab was given at initial dose of 4mg/kg,followed by weekly infusions at the dose of 2mg/kg.Results：In those patients,11.1% patients with CR（1/9）,66.7% patients with PR（6/9）.The disease control rate was 88.9%,and the medina time of tumor progression（TTP） was 18 months,and the medina time of overall survival was 23 months.The major grade 1-2 toxicities were myelosuppression and gastrointestinal reactions.Conclusion：Trastuzumab in combination with gemcitabine has clinically significant activity and safety in patients with refractory metastatic breast cancer.